DOACs vs Heparin in Cancer-Associated Thrombosis

As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.
Medscape Medical News

source https://www.medscape.com/viewarticle/986464?src=rss